The Breast Surgeon's Role in Risk-Reducing Medication Uptake

Area of Science:

• Oncology
• Pharmacology
• Preventive Medicine

Background:

• The role of breast surgeons is shifting due to advancements in breast cancer treatments and de-escalation of locoregional therapies.
• Precision pharmacological agents are increasingly important in combating breast cancer.
• There is a growing need for proactive breast cancer prevention strategies.

Purpose of the Study:

• To emphasize the evolving role of surgical breast oncologists in breast cancer prevention.
• To highlight the importance of risk-reducing medications (RRMEDS) for high-risk women.
• To address barriers to RRMEDS uptake and propose solutions.

Main Methods:

• Review of current trends in breast cancer treatment and prevention.
• Analysis of the role of surgical oncologists in patient counseling and management.
• Evaluation of the efficacy and tolerability of risk-reducing medications.

Main Results:

• Surgical breast oncologists should spearhead the development and implementation of preventive strategies.
• Patient understanding of breast cancer risk is crucial for initiating RRMEDS.
• Fear of side effects is a major barrier to RRMEDS uptake.

Conclusions:

• Low-dose tamoxifen shows promise in mitigating side effects and reducing attrition rates for women on RRMEDS.
• Integrating low-dose tamoxifen into the surgeon's armamentarium can improve RRMEDS adherence.
• Enhanced patient education and supportive pharmacological interventions are key to successful breast cancer risk reduction.